Overview

A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

Status:
Not yet recruiting
Trial end date:
2023-06-09
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess safety and tolerability of prostacyclin receptor agonist formulation in treatment period 1 and with different formulation of prostacyclin receptor agonist in treatment period 2.
Phase:
Phase 1
Details
Lead Sponsor:
Actelion
Treatments:
Epoprostenol
Tezosentan